Expression of prostaglandin E receptor subtype EP4 in conjunctival epithelium of patients with ocular surface disorders: case-control study
Authors:
Open Access
Abstract
Objectives: To confirm the downregulation of PTGER4 mRNA in the conjunctiva of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and ocular cicatricial pemphigoid (OCP) patients and to examine the expression of its EP4 protein in the conjunctival epithelium of patients with various ocular surface disorders. Design: Case-control study. Setting and participants: We performed quantitative reverse transcription-PCR (RT-PCR) analysis of PTGER4 mRNA in conjunctival tissue sections from patients with SJS/TEN and OCP to confirm the downregulation of PTGER4 mRNA expression. We also analysed EP4 immunohistologically in other ocular surface disorders. Conjunctival tissues were obtained from patients undergoing surgical reconstruction of the ocular surface due to chemical eye burns, subacute SJS/TEN or chronic SJS/TEN, chronic OCP, severe graft versus host disease (GVHD) and from patients with Mooren's ulcers treated by resection of the inflammatory conjunctiva. Primary and secondary outcome measures: The expression of PTGER4 mRNA and EP4 protein assessed by quantitative RT-PCR assay and immunohistological methods. Results: PTGER4 mRNA was significantly lower in conjunctival tissues from SJS and OCP patients than in the control conjunctivochalasis samples. EP4 protein was detected in conjunctival epithelium from patients with chemical eye burn and in control conjunctival epithelium from patients with conjunctivochalasis. Its expression varied in conjunctival epithelium from patients with Mooren's ulcer. We did not detect EP4 immunoreactivity in conjunctival epithelium from patients with subacute SJS/TEN, severe GVHD, chronic SJS/TEN or OCP. Conclusions: The strong downregulation of EP4 expression in conjunctival epithelium from patients with OCP or SJS/TEN may be attributable to ocular surface inflammation.Keywords
This publication has 10 references indexed in Scilit:
- Prostaglandin E2 suppresses polyinosine-polycytidylic acid (polyI:C)-stimulated cytokine production via prostaglandin E2 receptor (EP) 2 and 3 in human conjunctival epithelial cellsBritish Journal of Ophthalmology, 2011
- Prostaglandin E Receptor 4 Expression in Human Conjunctival Epithelium and Its Downregulation in Devastating Ocular Surface Inflammatory DisordersArchives of Ophthalmology (1950), 2010
- Prostaglandin E2–EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansionNature Medicine, 2009
- Prostaglandin E2 is a major soluble factor produced by stromal cells for preventing inflammatory cytokine production from dendritic cellsInternational Immunology, 2008
- Prostaglandin E2 Suppresses Lipopolysaccharide-Stimulated IFN-β ProductionThe Journal of Immunology, 2008
- Prostaglandin Receptor Signaling in DiseaseThe Scientific World Journal, 2007
- Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 ReceptorJournal of Biological Chemistry, 2002
- The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gutJournal of Clinical Investigation, 2002
- The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gutJournal of Clinical Investigation, 2002
- Cellular localization of mRNAs for prostaglandin E receptor subtypes in mouse gastrointestinal tractAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 1997